AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $5.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$5.3M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 5 added, 1 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Oct 1- Open
- $221.96
- 52-wk high
- $281.89
- High
- $224.22
- 52-wk low
- $179.75
- Low
- $220.32
- Prev close
- $222.10
- Mkt cap
- $32.14B
- P/E
- 21.3x
- Volume
- 949.4K
- Fwd P/E
- 18.5x
- Beta
- 0.77
- Div yield
- 1.08%
- P/S
- 5.7x
- P/B
- 4.9x
- Profit margin
- +27.0%
- Op margin
- +30.9%
- ROE
- +24.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about RMD filings
Are insiders buying or selling ResMed Inc (RMD) stock?
Net selling: insiders sold $5.3M and bought $0 of RMD stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $5.3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Farrell, Michael J. (Chairman and CEO), who sold $3.2M. The latest filing was on Sep 10, 2026.
Which members of Congress have traded RMD recently?
None. No member of Congress disclosed a RMD trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this RMD smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- AQ
AQR
$99.3M
added
- MI
Millennium
$61.0M
added
- CI
Citadel
$24.5M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in RMD right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 1.7% above what analysts expected.
Earnings per share
$2.90 expected
Reports Oct 29, 2026, in 28 days
Estimates as of Sep 30, 2026
EPS expected
$2.62 to $2.76
Revenue expected
17 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.34B | $1.42B | $1.43B | $1.46B |
| Cost of what it sold | $514.8M | $538.1M | $540.4M | $602.4M |
| Gross profit | $820.8M | $884.7M | $891.0M | $861.2M |
| What it spent | ||||
| Research and development | $87.3M | $91.0M | $94.3M | $105.7M |
| Sales and admin | $259.2M | $278.4M | $285.7M | $296.3M |
| Other operating costs | $27.8M | $17.7M | $11.2M | $10.5M |
| Total operating expenses | $374.3M | $387.1M | $391.2M | $412.5M |
| What was left | ||||
| Operating profit | $446.5M | $497.6M | $499.8M | $448.7M |
| Interest on debt | $8.8M | $7.9M | $12.3M | $20.9M |
| Profit before tax | $446.8M | $496.1M | $502.3M | $474.2M |
| Tax | $98.3M | $103.6M | $103.6M | $90.7M |
| Net profit | $348.5M | $392.6M | $398.7M | $383.4M |
| EBITDA | $503.3M | $566.4M | $583.6M | $493.0M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
35 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Can ResMed (ASX:RMD) Hit Its Outlook After Retiring the Astral Ventilator?
NeutralSep 30Net debt of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAN:RMEA
NeutralSep 30Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
Leans bullishSep 28ResMed stock last trades at USD 219.41 on September 28, 2026
NeutralSep 28ResMed Inc. (NYSE:RMD) Receives Consensus Recommendation of "Hold" from Brokerages
NeutralSep 26ResMed (RMD) Stock Forecast and Price Target 2026 $RMD
Leans bullishSep 26ResMed stock trades at USD 221.89 after RBC target hike
BullishSep 25ResMed stock heads into the open after September 24 data
NeutralSep 25